您的购物车当前为空
GIP Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 34.9 kDa and the accession number is P09681.

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5 μg | ¥ 493 | 6-8日内发货 | |
| 10 μg | ¥ 790 | 6-8日内发货 | |
| 20 μg | ¥ 1,330 | 5日内发货 | |
| 50 μg | ¥ 2,580 | 5日内发货 | |
| 100 μg | ¥ 5,170 | 5日内发货 |
| 生物活性 | Immobilized Human GIP, hFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-GIP Antibody, hFc Tag with the EC50 of 88.1 ng/ml determined by ELISA. |
| 产品描述 | GIP Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 34.9 kDa and the accession number is P09681. |
| 种属 | Human |
| 表达系统 | HEK293 Cells |
| 标签 | C-hFc |
| 蛋白编号 | P09681 |
| 别名 | GIP,gastric inhibitory polypeptide |
| 蛋白构建 | Glu22-Gln93 |
| 蛋白纯度 | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| 分子量 | 34.9 kDa (Predicted); 40-50 kDa (Due to glycosylation) |
| 内毒素 | Less than 1EU per μg by the LAL method. |
| 蛋白性状 | Lyophilized powder |
| 缓冲液 | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| 复溶方法 | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
| 存储 | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| 运输方式 | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
| 研究背景 | The potential application of glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide, GIP) in the management of obesity and type 2 diabetes has been controversial. Initial interest in the therapeutic use of GIP was dampened by evidence that its insulinotropic activity was reduced in type 2 diabetes and by reports that it increased glucagon secretion and adipose deposition in non-diabetic individuals. |